Articles

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma

Onco-Hematology Department, Grenoble University Hospital;INSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble-Alpes, Institute for Advanced Biosciences, Grenoble
Hematology Department, Annecy Hospital
Hematology Department, Brest University Hospital
Pathology Department, Nantes University Hospital
Onco-Hematology Department, Grenoble University Hospital
Hematology Department, Montpellier University Hospital
Hematology Department, Cancer Institute Bergonie Bordeaux
Hematology Department, Rennes University Hospital
Hematology Department, Tours University Hospital
Hematology Department, Dunkerque Hospital
Hematology Department, Chambery Hospital
Hematology Department, Bayonne Hospital
Hematology Department, Loire Cancer Institute, Saint Etienne
Lymphoid Malignancies Unit, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil
IHBN - Hematology Department, Caen University Hospital
Hematology Department, Clermont-Ferrand Cancer Institute
Hematology Department, Rouen University Hospital
Hematology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud. INSERM 1052
Hematology Department, Amiens University Hospital
Hematology Department, Nancy University Hospital
Hematology Department, University Hospital Strasbourg
Hematology Department, University Clermont-Ferrand Hospital
Hematology Department, Metz University Hospital
Hematology Department, Bordeaux University Hospital
Hematology Department, University Hospital Paris Saint-Louis
Hematology Department, Saint Quentin Hospital
Hematology Department, Chalon Hospital
Hematology Department, Corbeil Hospital
Hematology Department, Victor Hugo Clinic, Le Mans
Hematology Department, Catherine de Sienne Clinic, Nantes
Hematology Department, Angers University Hospital
Hematology Department, Avignon Hospital
Hematology Department, Besançon University Hospital
Hematology Department, Mulhouse Hospital
Hematology Department, Orleans Hospital
Onco-Hematology Department, University Hospital Poitiers and INSERM, CIC 1402, Poitiers University
Hematology Department, Baclesse Caen Cancer Center
Hematology Department, Toulouse University Hospital
Hematology Department, Nantes University Hospital
INSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble-Alpes, Institute for Advanced Biosciences, Grenoble;Unit for Innovation in Genetics and Epigenetics in Oncology, Dijon University Hospital, France
Vol. 104 No. 1 (2019): January, 2019 https://doi.org/10.3324/haematol.2018.191429